Hosted on MSN12mon
Teva’s Ajovy yields positive data in post-hoc migraine analysisThe Phase III trial evaluated the safety and efficacy of monthly and quarterly subcutaneous injections of Ajovy compared to placebo in subjects with chronic migraine or episodic migraine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback